Biotech stock sends Wall Street surprising signal

Дата публикации: 23-06-2026 18:47:00

Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is not a simple optimism. It’s prejudiced. Biotech businesses might toss around early research, big potential markets, and future ...

Классификация: Экономика

Схожие новости

#	Наименование новости	Тональность	Информативность
1	SEC Settles Insider Trading Suit Against Biotech Investor	0	0
2	Sharp drops in Big Tech companies pull stocks lower on Wall Street	0	0
3	Bill Ackman just showed what’s inside his $5B fund	0	0
4	South Korean stocks plunge on AI overvaluation fears	0	0
5	DeepSeek's Valuation Soars To $50B, Plus More Rumors	0	0
6	Pandemic darlings Moderna, BioNTech are now on two different paths	0	0
7	Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda	0	0
8	UCB acquires Candid Therapeutics in $2.22bn deal	0	0
9	ВТБ: объем продаж фондов прямых инвестиций вырастет вдвое	0	0
10	Börsengang: Bending Spoons vor Milliarden-IPO an der Nasdaq	0	0

• Тональность 0
• Информативность 0
• www.thestreet.com